{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:26:25Z","timestamp":1792589185302,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,8,23]]},"DOI":"10.7759\/cureus.67586","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:05:44Z","timestamp":1724418344000},"source":"Crossref","is-referenced-by-count":1,"title":["Dermatological Manifestations of Disseminated Bacillus Calmette-Guerin Infection in the Intensive Care Unit"],"prefix":"10.7759","author":[{"given":"Quentin","family":"Sarol\u00e9a","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"Ziraldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Pothen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leo-Paul","family":"Secco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Collienne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1590\/S1806-37132015000000126","article-title":"BCGitis: a rare complication after intravesical BCG therapy","volume":"41","author":"Oliveira MJ","year":"2015","unstructured":"Oliveira MJ, Vaz D, Carvalho A, Braga R, Duarte R. BCGitis: a rare complication after intravesical BCG therapy. J Bras Pneumol. 2015, 41:480-481. 10.1590\/S1806-37132015000000126","journal-title":"J Bras Pneumol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/bju.14793","article-title":"The epidemiology of bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study","volume":"124","author":"Larsen ES","year":"2019","unstructured":"Larsen ES, Nordholm AC, Lillebaek T, Holden IK, Johansen IS. The epidemiology of bacille Calmette-Gu\u00e9rin infections after bladder instillation from 2002 through 2017: a nationwide retrospective cohort study. BJU Int. 2019, 124:910-916. 10.1111\/bju.14793","journal-title":"BJU Int"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2020.11.037","article-title":"BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review","volume":"39","author":"Cabas P","year":"2021","unstructured":"Cabas P, Rizzo M, Giuffr\u00e8 M, et al.. BCG infection (BCGitis) following intravesical instillation for bladder cancer and time interval between treatment and presentation: a systematic review. Urol Oncol. 2021, 39:85-92. 10.1016\/j.urolonc.2020.11.037","journal-title":"Urol Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000000119","article-title":"Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature","volume":"93","author":"P\u00e9rez-Jacoiste As\u00edn MA","year":"2014","unstructured":"P\u00e9rez-Jacoiste As\u00edn MA, Fern\u00e1ndez-Ruiz M, L\u00f3pez-Medrano F, et al.. Bacillus Calmette-Gu\u00e9rin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore). 2014, 93:236-254. 10.1097\/MD.0000000000000119","journal-title":"Medicine (Baltimore)"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw376","article-title":"Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis","volume":"63","author":"Nahid P","year":"2016","unstructured":"Nahid P, Dorman SE, Alipanah N, et al.. Official American Thoracic Society\/Centers for Disease Control and Prevention\/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016, 63:e147-e195. 10.1093\/cid\/ciw376","journal-title":"Clin Infect Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.medj.2021.11.006","article-title":"Protection against tuberculosis by Bacillus Calmette-Gu\u00e9rin (BCG) vaccination: a historical perspective","volume":"3","author":"Setiabudiawan TP","year":"2022","unstructured":"Setiabudiawan TP, Reurink RK, Hill PC, Netea MG, van Crevel R, Koeken VA. Protection against tuberculosis by Bacillus Calmette-Gu\u00e9rin (BCG) vaccination: a historical perspective. Med. 2022, 3:6-24. 10.1016\/j.medj.2021.11.006","journal-title":"Med"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (TA, T1, and carcinoma in situ)","volume":"81","author":"Babjuk M","year":"2022","unstructured":"Babjuk M, Burger M, Capoun O, et al.. European Association of Urology guidelines on non-muscle-invasive bladder cancer (TA, T1, and carcinoma in situ). Eur Urol. 2022, 81:75-94. 10.1016\/j.eururo.2021.08.010","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14133073","article-title":"BCG in bladder cancer immunotherapy","volume":"14","author":"Jiang S","year":"2022","unstructured":"Jiang S, Redelman-Sidi G. BCG in bladder cancer immunotherapy. Cancers (Basel). 2022, 14:3073. 10.3390\/cancers14133073","journal-title":"Cancers (Basel)"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/s41585-018-0055-4","article-title":"Mechanisms of BCG immunotherapy and its outlook for bladder cancer","volume":"15","author":"Pettenati C","year":"2018","unstructured":"Pettenati C, Ingersoll MA. Mechanisms of BCG immunotherapy and its outlook for bladder cancer. Nat Rev Urol. 2018, 15:615-625. 10.1038\/s41585-018-0055-4","journal-title":"Nat Rev Urol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3109\/23744235.2015.1055794","article-title":"Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients","volume":"47","author":"Pommier JD","year":"2015","unstructured":"Pommier JD, Ben Lasfar N, Van Grunderbeeck N, et al.. Complications following intravesical bacillus Calmette-Guerin treatment for bladder cancer: a case series of 22 patients. Infect Dis (Lond). 2015, 47:725-731. 10.3109\/23744235.2015.1055794","journal-title":"Infect Dis (Lond)"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.11622\/smedj.2020168","article-title":"Intravesical Bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution","volume":"63","author":"Yang X","year":"2022","unstructured":"Yang X, Toh Q, Huang HH, Sng LH, Tan TT, Ng LG. Intravesical Bacillus Calmette-Guerin and its complications: 12 years of learning experience in a single local institution. Singapore Med J. 2022, 63:325-329. 10.11622\/smedj.2020168","journal-title":"Singapore Med J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3109\/09546634.2010.500325","article-title":"Cutaneous complication after BCG vaccination: case report and review of the literature","volume":"22","author":"Keijsers RR","year":"2011","unstructured":"Keijsers RR, Bovenschen HJ, Seyger MM. Cutaneous complication after BCG vaccination: case report and review of the literature. J Dermatolog Treat. 2011, 22:315-318. 10.3109\/09546634.2010.500325","journal-title":"J Dermatolog Treat"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1128\/jb.178.5.1274-1282.1996","article-title":"Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis","volume":"178","author":"Mahairas GG","year":"1996","unstructured":"Mahairas GG, Sabo PJ, Hickey MJ, Singh DC, Stover CK. Molecular analysis of genetic differences between Mycobacterium bovis BCG and virulent M. bovis. J Bacteriol. 1996, 178:1274-1282. 10.1128\/jb.178.5.1274-1282.1996","journal-title":"J Bacteriol"},{"key":"ref14","article-title":"McKee\u2019s Pathology of the Skin","author":"Calonje E","year":"2019","unstructured":"Calonje E, Brenn T, Lazar AJ, et al.. McKee\u2019s Pathology of the Skin. Elsevier , Philadelphia; 2019."},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/nri3211","article-title":"Revisiting the role of the granuloma in tuberculosis","volume":"12","author":"Ramakrishnan L","year":"2012","unstructured":"Ramakrishnan L. Revisiting the role of the granuloma in tuberculosis. Nat Rev Immunol. 2012, 12:352-366. 10.1038\/nri3211","journal-title":"Nat Rev Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/276669-dermatological-manifestations-of-disseminated-bacillus-calmette-guerin-infection-in-the-intensive-care-unit","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:05:46Z","timestamp":1724418346000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/276669-dermatological-manifestations-of-disseminated-bacillus-calmette-guerin-infection-in-the-intensive-care-unit"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,23]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.67586","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8,23]]}}}